Epione FDA Status Update

Epione Biopharmaceuticals recently completed an informal meeting with the FDA. Dr. Patricia Love, Deputy Director of Combination Devices Division at the FDA, met with the Epione team November 9, 2016. During the meeting, Dr. Love informally affirmed that the anticipated pathway using surrogate data on its existing APIs could allow approval in as little as 6-10 months.

Post navigation

Safe, non-addictive pain relief

Safe Harbor Statement

Our information may include predictions, estimates, or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this information. Please bear in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events.